Country Trust Bank decreased its holdings in Pfizer Inc. (NYSE:PFE) by 7.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 457,664 shares of the biopharmaceutical company’s stock after selling 38,129 shares during the quarter. Country Trust Bank’s holdings in Pfizer were worth $16,796,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the business. NewSquare Capital LLC raised its position in Pfizer by 0.4% in the 2nd quarter. NewSquare Capital LLC now owns 60,418 shares of the biopharmaceutical company’s stock valued at $1,976,000 after purchasing an additional 266 shares during the last quarter. Aevitas Wealth Management Inc. raised its position in Pfizer by 1.7% in the 2nd quarter. Aevitas Wealth Management Inc. now owns 15,916 shares of the biopharmaceutical company’s stock valued at $520,000 after purchasing an additional 269 shares during the last quarter. Cutter & CO Brokerage Inc. raised its position in Pfizer by 2.0% in the 2nd quarter. Cutter & CO Brokerage Inc. now owns 13,695 shares of the biopharmaceutical company’s stock valued at $448,000 after purchasing an additional 274 shares during the last quarter. Beaumont Asset Management L.L.C. raised its position in Pfizer by 1.3% in the 2nd quarter. Beaumont Asset Management L.L.C. now owns 21,244 shares of the biopharmaceutical company’s stock valued at $694,000 after purchasing an additional 276 shares during the last quarter. Finally, Dividend Assets Capital LLC raised its position in Pfizer by 0.9% in the 2nd quarter. Dividend Assets Capital LLC now owns 30,606 shares of the biopharmaceutical company’s stock valued at $1,001,000 after purchasing an additional 278 shares during the last quarter. Hedge funds and other institutional investors own 69.08% of the company’s stock.
In other Pfizer news, Director Ronald E. Blaylock bought 13,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was purchased at an average cost of $38.55 per share, with a total value of $501,150.00. Following the completion of the purchase, the director now owns 4,000 shares in the company, valued at $154,200. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.08% of the stock is currently owned by insiders.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The business had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. During the same period in the previous year, the firm earned $0.80 earnings per share. The firm’s quarterly revenue was down 11.0% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.89 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be paid a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.
Several equities analysts have issued reports on PFE shares. Mizuho reiterated a “buy” rating and issued a $43.00 price objective on shares of Pfizer in a research report on Tuesday, September 15th. ValuEngine downgraded Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, July 30th. Morgan Stanley boosted their target price on Pfizer from $36.00 to $42.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. Royal Bank of Canada set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Friday. Finally, Atlantic Securities downgraded Pfizer from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $44.00 to $39.00 in a research report on Monday, October 12th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company. Pfizer has a consensus rating of “Hold” and an average price target of $39.64.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: How to Trade Using Analysts Ratings
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.